Document:

Exhibit 4.21

 

STANDSTILL
AND OPTION AGREEMENT

 

This Agreement is made and entered into between
Perlegen Sciences Inc., having its principal office at 309 University Dr.,
Menlo Park CA, USA (hereinafter “Grantor”),
and Genetic Technologies Limited ACN 009 212 328, having its principal office
at 60-66 Hanover Street, Fitzroy, Victoria, Australia 3065 (hereinafter “Grantee”).

 

1.       Grant of Option. 
In consideration of the payment of the Option Fee by the Grantee to the
Grantor, the receipt of which the Grantor acknowledges, the Grantor grants the
Grantee an exclusive right during the Option Term to conduct due diligence
investigations on the Brevagen Assets and seek to agree formal documents to
purchase the Brevagen Assets from the Grantor in accordance with this Option
Agreement.

 

2.       Definitions.

 

a.       The Option Fee means that amount which the
Grantor and the Grantee agree shall be paid for the Option.   The
Option Fee shall be Nine Thousand One Hundred (USD 9,100) United States
Dollars.  The Grantee shall pay the
Option Fee within 14 days of execution of this Agreement.

 

b.      The Brevagen Assets means all the Grantor’s business assets which
include: the 7 SNP Validated Assay for Breast Cancer “BrevaGen” (and all
BrevaGen related materials including technical/validation, background/marketing
materials, intellectual property/licenses/know-how (including all BrevaGen
related patent filings (Genomic Analysis/Method filings and Breast Cancer
filings)), and customer research/lists required to manufacture, develop, create,
transfer, perform, distribute or sell the Brevagen test) , CLIA Accreditation,
Equipment including MASSArray machine, and The BrevaGen Sales and marketing
materials.

 

c.       Option
means the Grantee’s exclusive
right during the Option Term to conduct due diligence investigations on the
Brevagen Assets and seek to agree formal documents to purchase the Brevagen
Assets in accordance with the terms of this Option Agreement.

 

d.       The Option Term means the period of four (4) months
from the date of execution of this Agreement.

 

3.       Exercise of the
Option.  The Grantee may exercise the Option at any
time prior to expiration of the Option Term by giving written notice that it
wishes to acquire the Brevagen Assets. 
The notice must be signed by the Grantee and delivered to the Grantor at
its address stated above on or before the expiration of the Option Term.

 

4.       Confidentiality.  
Pursuant to the Confidentiality Agreement signed by the parties on or about 11 November 2009,
the parties agree to maintain proprietary information revealed pursuant to the
Option Agreement in confidence (other than as required by the ASX Listing
Rules), to disclose them only to persons within their respective companies or
professional advisers with a need to know, and to furnish assurances to the
other party that such persons understand this duty of confidentiality.

 

 

5.       Conditions to
Purchase.   During the Option Term:

 

a)      The Grantor must:

 

i.      promptly provide
all  due diligence materials reasonably
requested by Grantee;

ii.     ensure that, in providing
due diligence material and all reasonable assistance to the Grantee, the
material supplied by the Grantor is a bona fide reflection of the state of the
business and the Brevagen Assets;

iii.    maintain the Brevagen Assets
in good standing;

iv.    seek and receive
shareholder/stakeholder approval (if required) to sell the Brevagen Assets; and

v.     use reasonable
endeavours to prevent any event which may have a material adverse effect on the
value or viability of the Brevagen Assets.

 

b)      The Grantee must:

 

i.      complete all
technical, market, commercial, management, financial, tax, legal and IP due
diligence to the sole satisfaction of the Grantee;

ii.     raise sufficient
capital for it to to fund the transaction and the proposed BrevaGen product
re-launch; and

iii.    receive any and all
necessary shareholder, regulatory or third party approvals for the proposed
transaction.

 

6.       Option
Term.  The Grantor will not during
the Option Term, directly or indirectly, through any of its employees or any
adviser or representative retained by them canvass or solicit or encourage
(including, but not limited to, by way of providing any information or entering
into any form of agreement, arrangement or understanding) to initiate or
continue with any enquiries or proposals from any third parties regarding any
sale of part or all of the Brevagen Assets or similar transaction in relation
to the Brevagen Assets.

 

7.       Transaction
Structure and Terms of Sale of the Brevagen Assets. 
It is agreed that the proposed transaction for the sale and purchase of the
Brevagen Assets will reflect that, subject to any valid set-off, agreed between
the parties, as a result of the Grantee’s due diligence, the Brevagen Assets
have a maximum value of USD1,600,000 (which shall be made up of USD1,100,000 for
the 7 SNP Validated Assay, the MASSArray Equipment, The Sales and Marketing
Materials and either: a  USD500,000 fee or
4% royalty on BrevaGen sales at Grantee’s option). In addition, the parties may
wish to negotiate the sale of Perlegen’s remaining patent portfolio for up to
an additional USD1,000,000.

 

8.       Formal
Documents. The parties intend to seek to agree the terms and
conditions of a binding sale agreement in relation to the Brevagen Assets and
such other agreements as the parties may agree (“Formal Documents”) with a view to executing them as soon as
practicable and in any event on exercise of the Option.  However, there is no binding obligation for
the parties to enter into the Formal Documents and there is no binding agreement
until the parties execute the Formal Documents. 
The Formal Documents will (if entered into), in addition to reflecting
the basic commercial terms of this agreement include other provisions
ordinarily included in such documents.

 

9.       Expiry of Option. 
If the Grantee fails to exercise the Option before the expiration of the Option
Term this Option Agreement shall terminate and the Grantor may retain the
Option Fee and shall have no further obligation to the Grantee. If the parties meet the Conditions
to Purchase and an Asset Sale Agreement is secured, the Option Fee shall be
rebatable against the Purchase Price.

 

 

10.     Assignment. 
This Option Agreement shall bind and benefit the parties’ successors and
assigns.  Neither party may assign rights under this Option Agreement without
the prior written consent of the other party.

 

11.     Entire Agreement;
Amendment.  This Option Agreement contains the entire
agreement of the parties with respect to the transaction described herein, and
no prior or simultaneous oral or other written representations or promises
shall be a part of this Agreement or otherwise effective.  This Option
Agreement may not be amended or released, in whole or in part, except by a
document signed by both parties.

 

12.     Warranty.  
Grantor represents and warrants that the Grantor has clear title to, and is
free to sell the Brevagen Assets.  In
addition, the Grantor represents and warrants that the due diligence material
supplied by the Grantee is a bona fide reflection of the state of the business
and the Brevagen Assets.

 

13.     Law.
This Option Agreement shall be interpreted in accordance with the laws of
Colorado.

 

To evidence their agreement to the foregoing terms
and conditions, the Grantor and the Grantee have executed this Option Agreement
below:

 

Execution Date:     
December 2009

 

 

	
  SIGNED for and on
  behalf of Perlegen Sciences Inc.
  by its duly authorised representatives:

  	
   

  	
  SIGNED for and on
  behalf of Genetic Technologies Limited by
  its duly authorised representatives:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name: 

  	
   

  	
   

  	
  Name: 

  	
  Dr Paul MacLeman  

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title: 

  	
   

  	
   

  	
  Title:

  	
  Chief Executive Officer  

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
      December 2009

  	
   

  	
  Date:

  	
      December 2009Exhibit 10.1

 

AMENDMENT

 

This
Amendment amends the Zale Corporation Non-Employee Director Equity Compensation
Plan (the “Plan”) as heretofore amended.

 

WHEREAS,
the members of the Board of Directors of Zale Corporation, a Delaware
corporation (the “Company”), are compensated in part through awards under the
Plan;

 

WHEREAS,
the Plan currently provides that awards of options pursuant to Section 7
of the Plan shall have an exercise price equal to the “Fair Market Value” (as
defined in the plan) of a share of Company stock on the date the option is
granted; and

 

WHEREAS,
the Board of Directors concluded that it is in the best interests of the
Company’s shareholders to amend the Plan to permit awards with exercise prices
above, and not just equal to, the Fair Market Value, and approved such
amendment.

 

NOW,
THEREFORE, effective as of the date hereof the Plan is amended as follows:

 

1.             Section 7(a) of
the Plan is amended in its entirety to read as follows:  “The exercise price per share of an Option
shall be not less than the Fair Market Value of a share of Company Stock on the
date the Option is granted.”

 

2.             Except as amended
hereby, the Plan shall remain in full force and effect.

 

IN WITNESS WHEREOF, the Company has executed this amendment as of the
23rd day of December, 2009.

 

	
   

  	
   

  	
  ZALE
  CORPORATION

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Its:Exhibit 10.2

 

Portions of this exhibit (the discount rate schedule contained in
Attachment B) have been omitted and separately filed with the Securities and
Exchange Commission with a request for confidential treatment. Such omissions
are designated as “[***].”

 

AMENDMENT NUMBER ONE

 

This Amendment (“Amendment No. 1”)
is made and entered into as of June 8, 2009

 

	
  BETWEEN:

  	
  CITI CARDS CANADA INC.,

  
	
   

  	
  a corporation organized and existing  under the laws of Ontario, having its  head office at the City of
  Mississauga,  in the
  Province of Ontario, 

  
	
   

  	
  (“Citi Cards”)

  
	
   

  	
  OF THE FIRST PART

  
	
   

  	
   

  
	
  AND:

  	
  ZALE CANADA CO.,

  
	
   

  	
  a corporation organized and existing  under the laws of Nova Scotia, having  its principal place of
  business for North  America at
  901 W. Walnut Hill Lane,  Irving, Texas, U.S.A. 75038, 

  
	
   

  	
  (“Zale”)

  
	
   

  	
  OF THE SECOND PART

  
	
   

  	
   

  
	
  AND:

  	
  TXDC, L.P.,

  
	
   

  	
  a limited partnership organized and existing  under the laws of the
  State of Texas, in theUnited States of America, having a place of  business at 901 W. Walnut
  Hill Lane, Irving,  Texas, U.S.A.
  75038, 

  
	
   

  	
  (“TXDC”)

  
	
   

  	
  OF THE THIRD PART

  

 

WHEREAS Citi Cards (as successor in interest to Citi
Commerce Solutions of Canada Ltd. by amalgamation, effective July 2,
2007), Zale and TXDC entered into a Private Label Credit Card Program Agreement
dated March 1, 2007 (“Agreement”);

 

WHEREAS Citi Cards, Zale and TXDC wish to make certain
amendments to the Agreement;

 

AND WHEREAS Citi Cards, Zale and TXDC intend that, except as
expressly set forth below, the terms and conditions of the Agreement shall
remain unmodified and shall continue in full force and effect;

 

NOW, THEREFORE, in consideration of the terms and
conditions herein contained and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged by each of the
Parties, Citi Cards, Zale and TXDC agree together as follows:

 

 

AMENDMENTS:  Effective as
of June 8, 2009, the Agreement shall be amended as follows:

 

1.             Amendments
to Section 2.:  Section 2. of the
Agreement is revised as follows:

 

(a)           The second paragraph of Section 2.(b)(i) of
the Agreement is deleted and replaced by the following provision:

 

“Citi Commerce will at all times solely control all aspects of the
operation of the Private Label Program, including Account Issuance Criteria
standards and credit policy, (e.g., the decision whether or not to extend
credit for any Applicant for a Credit Card, and if so, the amount of credit to
be extended, and whether or not to continue or terminate any individual
Account), customer service operations, collections policy and operations,
marketing fulfillment operations, and accounting operations. Notwithstanding
the foregoing, Citi Commerce shall give Zale at least sixty (60) days’ notice
of any change to its standards and policies that is a material change.  Except as otherwise provided in this
Agreement, Citi Commerce will be the sole and exclusive owner of all materials
used in connection with the operation of the Private Label Program.”

 

(b)           Section 2.(b)(ii)(1) of the
Agreement is revised by deleting the text “(as solely determined by Citi
Commerce, acting reasonably)” in the fifth and sixth lines.

 

(c)           Section 2.(b)(ii)(2) of the
Agreement is revised by deleting the text “(as solely determined by Citi
Commerce, acting reasonably)” in the seventh and eighth lines.

 

2.             Amendments
to Section 14.: Section 14. of the
Agreement is revised as follows:

 

(a)           Section 14.(a)(ii) is
revised by deleting the word “or” at the end of the sentence and inserting a
semi-colon in its place.

 

(b)           Section 14.(a)(iii) is revised
by deleting the period at the end of the sentence and inserting a semi-colon in
its place.

 

(c)           Section 14.(a) is
revised by adding the following new provision at the end:

 

“(iv)        Zale provides
written notice to Citi Commerce on or before June 30, 2009 that this
Agreement is terminated, with such termination to be effective on or before October 31,
2009.

 

(d)           Section 14.(b)(i) is
revised by adding the following new paragraph at the end:

 

2

 

(e)           “Without prejudice to any of
Citi Commerce’s other rights and remedies under this Agreement, Citi Commerce
shall not invoke Section 13.(a)(xii) of the Agreement as an Event
of Default during the period commencing on June 8, 2009 and ending on March 31,
2010, and thereafter shall invoke Section 13.(a)(xii) only upon
ninety (90) days’ written notice to Zale.”

 

3.             Amendment
to Section 15.:  Section  15. of
the Agreement is revised by deleting the first paragraph of Section 15.(a) (including
the heading) and inserting the following provision in its place:

 

“Purchase Option:  In the event of the termination, non-renewal
or expiration of this Agreement pursuant to any of the provisions of this
Agreement other than pursuant to Section 14.(a)(iv) of this
Agreement resulting from a Zale notice of termination or Section 14.(b)(i) of
this Agreement resulting from a Zale Event of Default, Zale has the option (the
“Purchase Option”) to purchase, or to arrange for an Affiliate of Zale
or for a third party to purchase, the Purchase Assets (as defined in Section 16.(a))
at an aggregate purchase price determined in accordance with Section 15.(b) (the
“Purchase Price”).”

 

4.             Amendment
to Attachment B:  Attachment B to the
Agreement is deleted in its entirety and replaced with the Attachment B
annexed hereto.

 

5.             General:

 

(a)           On and after the date hereof, each reference in the Agreement to “this
Agreement” and each reference to “the Agreement” in any and all other
agreements, documents and instruments delivered by Citi Cards, Zale or TXDC in
accordance with the Agreement will mean and be a reference to the Agreement, as
amended by this Amendment No. 1.

 

(b)           Except as specifically amended by this Amendment No. 1, the
Agreement will remain in full force and effect and is hereby ratified and
confirmed by the Parties.

 

(c)           In the event of any inconsistency or conflict between the Agreement and
this Amendment No. 1, the terms and conditions and provisions of this
Amendment No. 1 will govern and control.

 

(d)           Capitalized terms used and
not otherwise defined in this Amendment No. 1 will have the meanings
assigned to such terms in the Agreement.

 

6.             Governing
Law: This Amendment No. 1
will be governed by the laws of the jurisdiction set forth as the governing law
jurisdiction in the Agreement.

 

7.             Counterparts:  This Amendment No. 1 may be executed in one or
more counterparts and by different Parties in separate counterparts. All of
such 

 

3

 

counterparts will
constitute one and the same instrument and will become effective when one or
more counterparts of this Amendment No. 1 have been signed by a Party and
delivered to the other Party. Any Party may deliver an executed copy of this
Amendment No. 1 by facsimile transmission to another Party, and such delivery
will have the same force and effect as any other delivery of a manually signed
copy of this Amendment No. 1.

 

IN WITNESS WHEREOF Citi Cards, Zale and TXDC have
caused this Amendment No. 1 to be executed as of June 8, 2009 by
their proper officers or other representatives duly authorized in that behalf.

 

	
  CITI CARDS CANADA INC.

  	
   

  	
  ZALE CANADA CO.

  
	
  (as successor in interest
  to Citi Commerce  Solutions of
  Canada Ltd. by amalgamation, effective July 2, 2007)

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Robert A. Fleig

  	
   

  	
  Name:

  
	
   

  	
  Title:

  	
  General Counsel

  	
   

  	
  Title:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  TXDC, L.P.

  	
   

  	
   

  
	
  By: Zale Delaware, Inc.,
  its general partner

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  	
   

  

 

(With respect to Section 9.,
and  as expressly granted in

Section 18., of the Agreement)

 

4

 

Attachment B

 

Merchant Fees and Revenue
Sharing

 

1.             Merchant
Fees: Zale agrees to pay a
Merchant Fee for each net Card Sale transaction type described in the Discount
Rate Schedule set out hereinbelow equal to the product obtained by multiplying
the total dollar amount of the net Card Sale by the applicable net Card Sale
transaction type discount rate, as shown in the Discount Rate Schedule set out
hereinbelow.

 

Citi
agrees to refund a Merchant Fee to Zale for each Return of a net Card Sale of a
transaction type described in the Discount Rate Schedule set out hereinbelow
equal to the product obtained by multiplying the total dollar amount of the
Return for the net Card Sale by the applicable net Card Sale transaction type
discount rate, as shown in the Discount Rate Schedule set out hereinbelow.

 

Citi
Commerce will provide Zale with written notice of any change to any Merchant
Fee hereunder at least thirty (30) days prior to the implementation of any such
change by Citi Commerce.

 

DISCOUNT
RATE SCHEDULE

 

	
  Card Sale Transaction Type

  	
   

  	
  Discount Rate

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Three (3) Month Same as Cash

  	
   

  	
  [***]

  	
  %

  
	
  Six (6) Month Same as Cash

  	
   

  	
  [***]

  	
  %

  
	
  Twelve (12) Month Same as Cash

  	
   

  	
  [***]

  	
  %

  
	
  Revolve

  	
   

  	
  [***]

  	
  %

  

 

2.       Revenue Sharing
Payments: Citi Commerce will pay to Zale, by not later than ten (10) Business
Days following the end of each calendar month, the applicable amount of the
Late Fee Revenue Rebate that has accrued in respect of Accounts under the
Private Label Program during such calendar month (hereinafter called “Revenue
Sharing Payments”).

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]